Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Ronald L. Dubowy"'
Autor:
Neil J. Clendeninn, Prabhu Rajagopalan, Michael Jeffers, Ronald L. Dubowy, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Beth Sheedy, Wen W. Ma, Grace K. Dy, Ramesh K. Ramanathan, Glen J. Weiss, Karl D. Lewis, Lia Gore, S. Gail Eckhardt, Diane P. Leffingwell, Alex A. Adjei, Daniel D. Von Hoff, Colin D. Weekes
Purpose: To evaluate the safety, pharmacokinetics, and pharmacodynamics of BAY 86-9766, a selective, potent, orally available, small-molecule allosteric inhibitor of mitogen-activated protein kinase 1/2 in patients with advanced solid tumors.Experime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15dee10b1d3e60f3bddbcf748ba9c9fa
https://doi.org/10.1158/1078-0432.c.6521624
https://doi.org/10.1158/1078-0432.c.6521624
Autor:
Neil J. Clendeninn, Prabhu Rajagopalan, Michael Jeffers, Ronald L. Dubowy, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Beth Sheedy, Wen W. Ma, Grace K. Dy, Ramesh K. Ramanathan, Glen J. Weiss, Karl D. Lewis, Lia Gore, S. Gail Eckhardt, Diane P. Leffingwell, Alex A. Adjei, Daniel D. Von Hoff, Colin D. Weekes
Table S1: Dose-limiting toxicities; Table S2:Multiple-dose pharmacokinetic parameters (geometric mean (%CV) of BAY 86-9766 and metabolite M17 on Course 1, Day 22 (representing exposure after 15 days of continuous dosing) for once-daily dosing cohorts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::645195f61f0c767c06b724819cf4f1ab
https://doi.org/10.1158/1078-0432.22449329.v1
https://doi.org/10.1158/1078-0432.22449329.v1
Autor:
Neil J. Clendeninn, Prabhu Rajagopalan, Michael Jeffers, Ronald L. Dubowy, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Beth Sheedy, Wen W. Ma, Grace K. Dy, Ramesh K. Ramanathan, Glen J. Weiss, Karl D. Lewis, Lia Gore, S. Gail Eckhardt, Diane P. Leffingwell, Alex A. Adjei, Daniel D. Von Hoff, Colin D. Weekes
Legend for supplementary figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4075ee0a6ba696a2cc8a2e2623ba5399
https://doi.org/10.1158/1078-0432.22449335.v1
https://doi.org/10.1158/1078-0432.22449335.v1
Autor:
Neil J. Clendeninn, Prabhu Rajagopalan, Michael Jeffers, Ronald L. Dubowy, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Beth Sheedy, Wen W. Ma, Grace K. Dy, Ramesh K. Ramanathan, Glen J. Weiss, Karl D. Lewis, Lia Gore, S. Gail Eckhardt, Diane P. Leffingwell, Alex A. Adjei, Daniel D. Von Hoff, Colin D. Weekes
Treatment schema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a906ec27133370e1ec606fb43c97986
https://doi.org/10.1158/1078-0432.22449332
https://doi.org/10.1158/1078-0432.22449332
Autor:
Alison Sehgal, Daanish Hoda, Peter A. Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard Hildebrandt, John E. Godwin, Patrick Michael Reagan, Nina D. Wagner-Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Ronald L. Dubowy, Aleco D’Andrea, Lei Wang, Leo I. Gordon
Publikováno v:
Journal of Clinical Oncology. 40:7062-7062
7062 Background: Pts with R/R LBCL after first-line (1L) treatment (tx) who are unable to undergo high-dose chemotherapy (HDCT) and HSCT have poor outcomes and limited tx options. PILOT (NCT03483103) evaluated liso-cel, an autologous, CD19-directed c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ddbbf4b2067d9ba275f07d80cd9e09f
https://doi.org/10.1200/jco.2022.40.16_suppl.7062
https://doi.org/10.1200/jco.2022.40.16_suppl.7062
Autor:
Leo I. Gordon, Daanish Hoda, Ling Shi, Shien Guo, Fei Fei Liu, Julia Braverman, Ronald L. Dubowy, Lily Peng, Alison Sehgal
Publikováno v:
Journal of Clinical Oncology. 40:6567-6567
6567 Background: PILOT (NCT03483103) evaluated liso-cel, an autologous, CD19-directed, CAR T cell product, as 2L tx in pts with R/R LBCL not intended for HSCT. We analyzed changes in health-related quality of life (QOL) with respect to functioning an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37775ce2cec23483951676e04c7fb178
https://doi.org/10.1200/jco.2022.40.16_suppl.6567
https://doi.org/10.1200/jco.2022.40.16_suppl.6567
Autor:
Veerendra Munugalavadla, Lin Gu, Andrew D. Zelenetz, Jennifer R. Brown, Susan O'Brien, Richard R. Furman, Tadeusz Robak, Peter Hillmen, Anthony R. Mato, Marco Montillo, Ronald L. Dubowy, Nicole Lamanna
Publikováno v:
Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c8ef9fefa5b8aa43cda22854244dfd9
https://pubmed.ncbi.nlm.nih.gov/32655145
https://pubmed.ncbi.nlm.nih.gov/32655145
Autor:
Veerendra Munugalavadla, Barbara Eichhorst, Michael Hallek, Susan O'Brien, Esther Lilienweiss, Andrew R. Pettitt, Peter Hillmen, Richard R. Furman, Karl-Anton Kreuzer, Paula Cramer, Hans Christian Reinhardt, Yeonhee Kim, Ronald L. Dubowy, Stephan Stilgenbauer
Publikováno v:
Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::928f59ffc8fc5dafe00e5cae15e17fbe
Autor:
Andrew D. Zelenetz, Ronald L. Dubowy, Jeffrey A. Jones, Jacob D. Soumerai, Richard R. Furman, Ai Ni, Jeffrey P. Sharman, Julie Huang, Michael Hallek, Lyndah Dreiling, Adeboye H. Adewoye, Guan Xing
Publikováno v:
Leuk Lymphoma
The CLL-IPI is a risk-weighted prognostic model for previously untreated patients with chronic lymphocytic leukemia (CLL), but has not been evaluated in patients with relapsed CLL or on novel therapies. We evaluated the CLL-IPI in 897 patients with r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::239379e223c706a37ccf312222142c1a
https://doi.org/10.1080/10428194.2018.1540782
https://doi.org/10.1080/10428194.2018.1540782
Autor:
Ian W. Flinn, Ronald L. Dubowy, Steven Coutre, Yeonhee Kim, David W. Johnson, Siddhartha Mitra, Jan A. Burger, Andrew D. Zelenetz, Albert S. Yu, Michael J. Keating, Langdon L. Miller, Nicole Lamanna, Susan O'Brien, Leanne Holes, Thomas J. Kipps, Roger Dansey
Publikováno v:
Blood. 126:2686-2694
Idelalisib is a first-in-class oral inhibitor of PI3Kδ that has shown substantial activity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). To evaluate idelalisib as initial therapy, 64 treatment-naive older patients with CLL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e69695ec278100b3df187745f246e6
https://doi.org/10.1182/blood-2015-03-630947
https://doi.org/10.1182/blood-2015-03-630947